Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7255 results

Sort By:

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Study ID: NCT06518057
Start Date: 2025-03-03
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

22

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Electronic Health Record Review

Lumbar Puncture

Magnetic Resonance Imaging

Positron Emission Tomography

Proton Beam Craniospinal Irradiation

Survey Administration

Volume Modulated Arc Therapy

Hippocampal-Avoidance Craniospinal Irradiation

Sponsor

University of Washington

Source: clinicaltrials.gov

Share:
Add to list

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Study ID: NCT06898957
Start Date: 2025-05-16
End Date: 2031-04-13
Study Type

Interventional

Study Phase

Phase1

No. of Participants

200

Intervention / Treatment

YL201

Liquid

Atezolizumab

Durvalumab

Sponsor

Amgen

Source: clinicaltrials.gov

Share:
Add to list

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Study ID: NCT03972657
Start Date: 2019-08-12
End Date: 2026-07-03
Study Type

Interventional

Study Phase

Phase2

No. of Participants

345

Intervention / Treatment

REGN5678

Cemiplimab

Sponsor

Regeneron Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma

Study ID: NCT05956457
Start Date: 2023-09-15
End Date: 2026-08-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Digital Health Coaching Program

Fitbit

Sponsor

Pack Health

Source: clinicaltrials.gov

Share:
Add to list

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

Study ID: NCT04841148
Start Date: 2021-06-01
End Date: 2028-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

96

Intervention / Treatment

HCQ

Avelumab

Palbociclib

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

Study ID: NCT06617858
Start Date: 2024-12-04
End Date: 2028-02-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

15

Intervention / Treatment

With-05x

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Study ID: NCT04267848
Start Date: 2020-06-16
End Date: 2025-12-15
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1210

Intervention / Treatment

Biospecimen Collection

Carboplatin

Cisplatin

Computed Tomography

Echocardiography Test

Gemcitabine Hydrochloride

Magnetic Resonance Imaging

Observation Activity

Paclitaxel

Pembrolizumab

Pemetrexed Disodium

Administration questionnaire

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Daratumumab in STK11 Mutated NSCLC

Study ID: NCT05807048
Start Date: 2023-06-01
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

14

Intervention / Treatment

Daratumumab and Hyaluronidase-fihj

Pre-Intervention Medication

Post-Intervention Medication

Sponsor

NYU Langone Health

Source: clinicaltrials.gov

Share:
Add to list

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Study ID: NCT04616248
Start Date: 2023-01-09
End Date: 2027-01-09
Study Type

Interventional

Study Phase

Phase1

No. of Participants

18

Intervention / Treatment

Anti-CD40 Agonist Monoclonal Antibody CDX-1140

Poly ICLC

Radiation Therapy

Recombinant Flt3 Ligand

Pembrolizumab

Tocilizumab

Sponsor

University of Southern California

Source: clinicaltrials.gov

Share:
Add to list

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Study ID: NCT04678648
Start Date: 2021-03-03
End Date: 2027-01-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

134

Intervention / Treatment

RSC-1255 Dose Escalation

RSC-1255 Dose Expansion

Sponsor

RasCal Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list